Shanghai Shyndec Pharmaceutical Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Yong Liu

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	2yrs
Promedio de permanencia en la Junta Directiva	3.6yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Yong Liu (55 yo)

less than a year

Permanencia

Mr. Yong Liu is Vice Chairman of the Board of Shanghai Shyndec Pharmaceutical Co., Ltd. from April 28, 2021 and serves as President Since September 2024.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Yong Liu	Vice Chairman of the Board & President	less than a year	sin datos	sin datos
Xian Lin Li	VP & General Counsel	2.6yrs	CN¥1.43m	0.0015% CN¥ 241.8k
Dongsong Wei	VP & Secretary of the Board of Directors	13.3yrs	CN¥1.46m	0.0015% CN¥ 241.8k
Feng Ni	Vice President	2yrs	CN¥914.60k	0.0015% CN¥ 241.8k
Jing Zu	Chief Financial Officer	less than a year	CN¥344.90k	sin datos

2.0yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 600420 se considera experimentado (2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yong Liu	Vice Chairman of the Board & President	3.6yrs	sin datos	sin datos
Yingqi Li	Independent Director	2yrs	CN¥240.00k	sin datos
Peng Wang	Director	2yrs	sin datos	sin datos
Ru Li	Director	2yrs	sin datos	sin datos
Zenghe Dong	Chairman	5.8yrs	sin datos	sin datos
Xiangdong Yu	Supervisor	5.8yrs	sin datos	0.0015% CN¥ 241.8k
Kan Tian	Independent Director	5.8yrs	CN¥240.00k	sin datos
Yonggang Xing	Chairman of the Supervisory Board	5yrs	sin datos	sin datos
Shuyuan Wei	Director	4.5yrs	sin datos	sin datos
Fanhong Wu	Independent Director	3.6yrs	CN¥240.00k	sin datos
Yonghua Zuo	Supervisor	2yrs	sin datos	sin datos

3.6yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de 600420 se considera experimentada (3.6 años de antigüedad promedio).

Shanghai Shyndec Pharmaceutical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Shanghai Shyndec Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 3Q 2023)

Investor sentiment deteriorates as stock falls 15%

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.13 in 2Q 2023)

Investor sentiment improves as stock rises 17%

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Shanghai Shyndec Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024

First quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.15 in 1Q 2023)

Investor sentiment improves as stock rises 15%

Full year 2023 earnings released: EPS: CN¥0.54 (vs CN¥0.61 in FY 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in FY 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 2Q 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

First quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.076 in 1Q 2022)

Investor sentiment improves as stock rises 20%

Full year 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.55 in FY 2021)

Shanghai Shyndec Pharmaceutical Co., Ltd. announced that it has received CNY 1.199999999 billion in funding from China National Pharmaceutical Group Corporation

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.20 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.20 in 2Q 2021)

Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) dropped from S&P Global BMI Index

Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) dropped from S&P Global BMI Index

First quarter 2022 earnings released: EPS: CN¥0.076 (vs CN¥0.21 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.55 (vs CN¥0.63 in FY 2020)

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.30 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 2Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.13 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.63 (vs CN¥0.62 in FY 2019)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: CN¥8.47

New 90-day low: CN¥9.01

New 90-day low: CN¥9.42

New 90-day high: CN¥10.68

Third quarter earnings released

New 90-day low: CN¥9.49

First half earnings released

New 90-day high - CN¥10.64

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad